论文部分内容阅读
目的研究高效抗逆转录病毒疗法(HAART)在艾滋病(HIV)患者中的应用。方法入选2013年6月至2015年1月本院收治的艾滋病患者60例为研究对象,对所有患者均给予高效抗逆转录病毒疗法,采取联合治疗:拉米夫定0.3 g qd,齐多夫定0.3 g bid,依非韦伦600 mg qn。治疗后3,6,12个月,比较患者的CD4~+T淋巴细胞计数和HIV病毒载量变化,分析患者的临床疗效和药物不良反应。结果治疗12个月后患者的有效率为93.33%(56/60例)。CD4~+T淋巴细胞计数和病毒载量:与治疗前的(104.74±9.58)pcs·μL~(-1)、(7.76±0.42)g·copies·m L~(-1)比较,治疗3个月后分别为(144.64±6.47)pcs·μL~(-1)、(4.80±0.20)g·copies·m L~(-1),差异均有统计学意义(均P<0.05)。有7例患者发生骨髓抑制,5例发生肝毒性(在治疗后1,2个月出现),3例出现Ⅱ级末梢神经炎(在治疗后3,4,6个月出现)。结论 HAART疗法对HIV患者进行治疗,免疫学和病毒学效果良好。
Objective To study the use of highly active antiretroviral therapy (HAART) in AIDS patients. Methods Sixty AIDS patients admitted to our hospital from June 2013 to January 2015 were enrolled in this study. All patients were given anti-retroviral therapy with high efficacy and anti-retroviral therapy. The combination therapy was lamivudine 0.3 g qd, Set 0.3 g bid, efavirenz 600 mg qn. At 3, 6 and 12 months after treatment, the CD4 ~ + T lymphocyte counts and HIV viral load were compared, and the clinical efficacy and adverse drug reactions were analyzed. Results The effective rate of patients after 12 months of treatment was 93.33% (56/60 cases). CD4 ~ + T lymphocyte count and viral load: Compared with pretreatment (104.74 ± 9.58) pcs · μL -1, (7.76 ± 0.42) g · m · m L -1, (144.64 ± 6.47) pcs · μL -1 and (4.80 ± 0.20) g · m · m L -1 after a month, respectively (all P <0.05). Seven patients had myelosuppression, five had hepatotoxicity (one or two months after treatment), and three had Grade II peripheral neuritis (three, four, and six months after treatment). Conclusion HAART therapy for HIV patients, immunology and virology good effect.